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ABSTRACT
Introduction. Mepolizumab (MEP) was commercialized in Italy since at least 2 years. Its efficacy 
was well confirmed in the real-life setting, but a predictive biomarker for efficacy still lacks. It 
was hypothesized that the magnitude of the response could be positively related to the baseline 
eosinophil count. Thus, we tested this hypothesis on our available population.
Methods. The analysis was performed on 138 patients, with severe asthma and who had received 
MEP for at least 1 year. The baseline eosinophil count was correlated to the change (12 months vs 
baseline) in several parameters: oral corticosteroids intake, FEV1, asthma control test score, 
number of exacerbations, fractional exhaled nitric oxide . 
Results. We analyzed 138 patients (78 females, 60 males, mean age 58±10 years). By using the 
Spearman and Pearson tests, no significant correlation could be found between the baseline 
eosinophil count and the percentage change in the considered parameters (r between -0.091 and 
0.093; p= NS).   
Conclusion. There is no detectable correlation between the baseline eosinophil count and the 
magnitude of the effects of MEP, although the efficacy remains confirmed. Under the present 
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FEV1: forced expiratory volume in 1 second
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To the editor,
the availability of monoclonal antibodies (MAbs) has changed the therapeutic approach to 
severe asthma, defined by the ERS/ATS document as asthma that remains not controlled despite 
the maximum inhaled treatment, and that often requires the use of systemic corticosteroids (OCS). 
So far, we can distinguish a type 2 asthma, characterized by eosinophilic inflammation, high 
fractional exhaled nitric oxide (FeNO) and frequently IgE sensitization. On the other hand we 
have the non T2 asthma, with poor inflammatory characteristics, non-eosinophilic inflammation, 
and poor response to OCS . The T2–type asthma offered intriguing strategies, such as anti IgE 
(Omalizumab) and anti-IL-5(R) MAbs (Mepolizumab, Reslizumab, Benralizumab) [1]. It is 
necessary to look for one or more biomarkers able to predict the clinical response, in order to 
prescribe the biological treatment with a reasonable expectancy of success.
In the case of biological agents, some markers have been proposed as possibly predictive, 
such as peripheral blood eosinophils (EOS), FeNO, periostin and total IgE. In the specific case of 
T2 asthma, where the antagonism to IL-5 (either circulating or receptor-directed) is considered of 
primary relevance, the eosinophil count (cells/μL) was suggested as a reliable predictive 
biomarker. The hypothesis that as high is the pre-treatment eosinophil count, as better would be 
the clinical response, was apparently confirmed in the phase III regulatory trials [2-4]. In this 
context, it must be considered that the patients enrolled in the phase III trials are different from 
those treated in the real-life context [5]. 
In this analysis we attempted to correlate the baseline EOS count with the clinical,  
functional and biological outcome changes, to assess if baseline EOS could be a predictive 
biological marker.
All the patients, diagnosed with severe asthma according to ERS/ATS criteria and which  
main comorbidities have been sought and treated [6], were followed-up by several nationwide 
distributed centers (Genoa, Pietra Ligure, Milan, Cuneo, Turin, Reggio Emilia, Verona, Rome, 
Arenzano, Brescia, Naples) and received MEP for at least 12 months. The general characteristics 
and their changes over 12 months of treatment are described elsewhere [7]. To assess this, the 
percentage change (12 months – baseline) was calculated for: OCS dose, asthma control test 
(ACT) score, FEV1,  exacerbation rate and FeNO.  The null hypothesis was that the baseline EOS 
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Changes in the considered parameters were first tested with a t-test for paired samples, or 
with Wilcoxon test for paired data when appropriate. Furthermore the probability level for the 
Wilcoxon test was computed using a complete randomisation method (permutation or exact test; 
Pexact) or by a Monte Carlo (PMonte Carlo).The type I error (α) has been set at the 0.01 level. The 
means were reported with their standard error (±SE). The percentage change from baseline of 
analyzed parameters used to estimate the association with EOS was performed by the Pearson 
Linear Correlation Analysis or Spearman non-parametric Correlation Coefficient when 
appropriate . All statistical analyses were performed using IBM® SPSS 25 (Chicago, IL, US).
In total, 138 patients (78 female, 60 male, mean age 58±10 years; age range 21-81), were 
observed. Of them, 27 were allergic (all to mite, and 18 also to pollen allergens). The main 
demographic and clinical characteristics of those patients, as already described in detail [7], are 
summarized in TABLE 1.
No significant linear associations (p > 0.05) were detected between the EOS count at 
baseline and the change at 12 months versus baseline of the examined parameters 
(Supplementary TABLE 1). Even when log-transformed to achieve normality, no correlation 
analysis could detect any significant linear association. 
The raw data are depicted in Figure 1 (A-E), where it is clear that the slopes of linear 
trends are minimal. In final, we could not detect any significant association between baseline 
eosinophils and the changes in the considered parameters. 
It was repeatedly hypothesized that the count, of peripheral eosinophils could be a 
predictive bio-marker for the response to IL-5 antagonism approach [4]. In this case we evaluated 
the observations made in real life patients. The basic hypothesis was that, according to literature, 
as higher were peripheral eosinophils as higher would be the response that can be measured (e.g. 
ACT, OCS intake, number of exacerbations, FEV1). The results of a sub-study [4] stratified the 
response on exacerbations rate related to baseline eosinophils, dividing subjects into three groups 
(2, 3, >4 exacerbations) and showed a significant positive correlation. We performed the same 
analysis taking into account multiple parameters and using, instead of a group categorization, the 
continuous linear trend. In the present study,  we could detect no clear significant correlation 
between baseline EOS count and the final outcomes after one year of treatment. The major 
weakness of the study may be the possible confounding action of the OCS treatment used by many 
patients, as often required in severe asthma. Nonetheless, since we have available several 
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appropriate prescription would optimal, and real life data could be useful for this aim, but 
currently we have only few observations [7-8]. Different biomarkers have been proposed 
(including eosinophils, FeNO, periostin, total IgE), but so far none of them proved to be 
applicable. Since eosinophils are considered a good candidate, we attempted to detect associations 
between the clinical, demographic and functional data in order to assess if EOS count could be 
related to the magnitude of the response (clinical/functional). It is true that this biological 
treatment could reduce the intake of OCS, the number of exacerbations [9] and, therefore, the 
overall cost of severe asthma, nonetheless a predictive value of baseline EOS could not be 
detected in this setting. 
Thus, we have to acknowledge that we are still unable to strictly identify a predictive 
biomarker, that can be easily managed and used in the real-life setting. What do we know for 
certain is that IL-5 antagonism (MEP in this case) is effective, but that EOS count at baseline, 
according to the results from our analysis, does not seem to represent a sufficient parameter to 
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Legend to Figure 1. The figure shows patient by patient the % change of parameters versus baseline 
(Y axis) and the baseline eosinophil count (X axis). The linear trend is indicated as a red line and the 
correlation coefficient is also reported. A: FEV1; B; FeNO; C: ACT score; D: OCS daily dose; E: 
Exacerbations in the past 12 months
TABLE 1: main characteristics of the patients at baseline and after 12 months of MEP treatment. 
The parameters for which the % change from baseline was considered in the statistical analysis are 
highlighted (from 11)
Characteristics Baseline 12 months Difference p-value
Number of patients 138 138 n.a. n.a.
Age (SD, range) 58 (10; 21-81) 59 (10; 22-82) - n.s.
Age onset (SD) 34 (17)
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FVC (%) 88 92 4.4 (5%) .021
FEV1/FVC (±SD) 0.65 (0.11) 0.69 (0.11) 0.04 (6%) .002
ACT (±SD) 17 (5) 22 (3) 5 (34%) <.0001
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